US2014220677A1PendingUtilityA1

Agents and method for treating inflammation-related conditions and diseases

58
Assignee: UNIV LOMA LINDAPriority: Feb 14, 2012Filed: Apr 4, 2014Published: Aug 7, 2014
Est. expiryFeb 14, 2032(~5.5 yrs left)· nominal 20-yr term from priority
Inventors:David J. BaylinkKin-Hing William LauXuezhong Qin
A61P 29/00A61K 38/44A61K 48/0058A61K 39/395C12N 15/85A61K 38/30A61K 38/18C12N 2740/15043A61K 45/06A61K 38/1841C12N 2840/20A61K 45/00C12Y 114/13013A61K 40/24A61K 40/416A61K 40/414A61K 40/22A61K 40/17A61K 2239/38A61K 2239/31
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . Gene-modified, inflammation-specific monocytes suitable for treating one or more than one inflammation-related condition or disease; the gene-modified, inflammation-specific monocytes comprising:
 a) a 1-alpha-hydroxylase gene that produces functional 1-alpha-hydroxylase when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages; and   b) a growth factor gene that produces functional growth factor when the gene-modified, inflammation-specific monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.   
     
     
         2 . The gene-modified, inflammation-specific monocytes of  claim 1 , where the 1-alpha-hydroxylase gene is a human 1-alpha-hydroxylase gene. 
     
     
         3 . The gene-modified, inflammation-specific monocytes of  claim 1 , where the 1-alpha-hydroxylase gene is on plasmid DNA or on a viral vector. 
     
     
         4 . The gene-modified, inflammation-specific monocytes of  claim 1 , where the growth factor gene is a human growth factor gene. 
     
     
         5 . The gene-modified, inflammation-specific monocytes of  claim 1 , where the growth factor gene is on plasmid DNA or on a viral vector. 
     
     
         6 . The gene-modified, inflammation-specific monocytes of  claim 1 , where the growth factor gene is selected from the group consisting of insulin-like growth factor 1 and a transforming growth factor beta gene. 
     
     
         7 . The gene-modified, inflammation-specific monocytes of  claim 1 , where the gene-modified, inflammation-specific monocytes are CD14-positive and CD16-negative monocytes. 
     
     
         8 . Gene-modified, inflammation-specific monocytes suitable for treating one or more than one inflammation-related condition or disease; the gene-modified, inflammation-specific monocytes comprising:
 a) a 1-alpha-hydroxylase gene that produces functional 1-alpha-hydroxylase when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages; and   b) a macrophage-specific promoter that limits expression of the 1-alpha-hydroxylase gene until the gene-modified, inflammation-specific monocytes transdifferentiate into gene-modified, inflammation-specific macrophages, where the promoter is functional under conditions of inflammation.   
     
     
         9 . The gene-modified, inflammation-specific monocytes of  claim 8 , where the 1-alpha-hydroxylase gene is a human 1-alpha-hydroxylase gene. 
     
     
         10 . The gene-modified, inflammation-specific monocytes of  claim 8 , where the 1-alpha-hydroxylase gene is on plasmid DNA or on a viral vector. 
     
     
         11 . The gene-modified, inflammation-specific monocytes of  claim 8 , where the macrophage-specific promoter is selected from the group consisting of CD11b, CD14, c-fms, Lysozyme M and Scavenger Receptor Class A. 
     
     
         12 . Gene-modified, inflammation-specific macrophages suitable for treating one or more than one inflammation-related condition or disease; the gene-modified, inflammation-specific macrophages comprising:
 a) a 1-alpha-hydroxylase gene that produces functional 1-alpha-hydroxylase; and   b) a growth factor gene that produces functional growth factor.   
     
     
         13 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the 1-alpha-hydroxylase gene is a human 1-alpha-hydroxylase gene. 
     
     
         14 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the 1-alpha-hydroxylase gene is on plasmid DNA or on a viral vector. 
     
     
         15 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the growth factor gene is a human growth factor gene. 
     
     
         16 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the growth factor gene is on plasmid DNA or on a viral vector. 
     
     
         17 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the growth factor gene is selected from the group consisting of insulin-like growth factor 1 and a transforming growth factor beta gene. 
     
     
         18 . The gene-modified, inflammation-specific macrophages of  claim 12 , further comprising a macrophage-specific promoter that limits expression of the 1-alpha-hydroxylase gene until the gene-modified, inflammation-specific macrophages transdifferentiate from gene-modified, inflammation-specific monocytes, where the promoter in functional under conditions of inflammation. 
     
     
         19 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the gene-modified, inflammation-specific macrophages are M2 macrophages. 
     
     
         20 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the gene-modified, inflammation-specific macrophages are Gr1-positive M2 macrophages. 
     
     
         21 . The gene-modified, inflammation-specific macrophages of  claim 12 , where the gene-modified, inflammation-specific macrophages are Mac1-positive macrophages. 
     
     
         22 . Gene-modified, inflammation-specific macrophages suitable for treating one or more than one inflammation-related condition or disease; the gene-modified, inflammation-specific macrophages comprising:
 a) a 1-alpha-hydroxylase gene that produces functional 1-alpha-hydroxylase; and   b) a macrophage-specific promoter that limits expression of the 1-alpha-hydroxylase gene until the gene-modified, inflammation-specific macrophages transdifferentiate from gene-modified, inflammation-specific monocytes, where the promoter in functional under conditions of inflammation.   
     
     
         23 . The gene-modified, inflammation-specific macrophages of  claim 22 , where the 1-alpha-hydroxylase gene is a human 1-alpha-hydroxylase gene. 
     
     
         24 . The gene-modified, inflammation-specific macrophages of  claim 22 , where the 1-alpha-hydroxylase gene is on plasmid DNA or on a viral vector. 
     
     
         25 . The gene-modified, inflammation-specific macrophages of  claim 22 , where the macrophage-specific promoter is selected from the group consisting of CD11b, CD14, c-fms, Lysozyme M and Scavenger Receptor Class A. 
     
     
         26 . The gene-modified, inflammation-specific macrophages of  claim 22 , where the gene-modified, inflammation-specific macrophages are M2 macrophages. 
     
     
         27 . The gene-modified, inflammation-specific macrophages of  claim 22 , where the gene-modified, inflammation-specific macrophages are Gr1-positive M2 macrophages. 
     
     
         28 . The gene-modified, inflammation-specific macrophages of  claim 22 , where the gene-modified, inflammation-specific macrophages are Mac1-positive macrophages. 
     
     
         29 . Gene-modified, inflammation-specific macrophages that have transdifferentiated from gene-modified, inflammation-specific monocytes according to  claim 1 . 
     
     
         30 . Gene-modified, inflammation-specific macrophages that have transdifferentiated from gene-modified, inflammation-specific monocytes according to  claim 8 . 
     
     
         31 . A pharmaceutical suitable for treating one or more than one inflammation-related condition or disease, the pharmaceutical comprising gene-modified, inflammation-specific monocytes according to  claim 1 . 
     
     
         32 . A pharmaceutical suitable for treating one or more than one inflammation-related condition or disease, the pharmaceutical comprising gene-modified, inflammation-specific monocytes according to  claim 8 . 
     
     
         33 . A pharmaceutical suitable for treating one or more than one inflammation-related condition or disease, the pharmaceutical comprising gene-modified, inflammation-specific macrophages according to  claim 12 . 
     
     
         34 . A pharmaceutical suitable for treating one or more than one inflammation-related condition or disease, the pharmaceutical comprising gene-modified, inflammation-specific macrophages according to  claim 22 .

Join the waitlist — get patent alerts

Track US2014220677A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.